These findings suggest that a subset of severe, therapy-resistant asthma patients may be characterized by elevated Tc2 cell formation and susceptible to treatment with biologics targeting IL-4 or IL-33 or components in their downstream signaling pathways2. Here, IL33 is linked to asthma.